论文部分内容阅读
人们首先在新生儿呼吸窘迫综合症 (ＮＲＤＳ)和急性呼吸窘迫综合症 (ＡＲＤＳ)中发现了肺表面活性物质 (ｐｕｌｍｏｎａｒｙｓｕｒｆａｃｔａｎｔ,ＰＳ)量的不足和功能失常 ,使用ＰＳ替代疗法在这些疾病的临床治疗上也已取得了重大进展 ,但对其与支气管哮喘的关系则了解甚少。?
People first found deficiencies and dysfunctions of pulmonarysurfactant (PS) in neonatal respiratory distress syndrome (NRDS) and acute respiratory distress syndrome (ARDS), and the use of PS replacement therapy in the clinical management of these diseases Significant progress has also been made, but little is known about its relationship to bronchial asthma. ?